Journal ArticleDOI
Response to: 'Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms' by Reginster et al.
Jos Runhaar,Rianne M Rozendaal,Marienke van Middelkoop,H. Bijlsma,Michael Doherty,Krysia Dziedzic,L. Stefan Lohmander,Timothy E. McAlindon,Weiya Zhang,Sita Bierma Zeinstra +9 more
TLDR
The eLetter authors do not put forward any critique of the publication that requires the authors' justification or clarification, and the effectiveness of oral glucosamine products for knee and hip OA symptoms has been questioned.Abstract:
We appreciate the interest that Reginster and colleagues1 showed in our publication on subgroup effects of oral glucosamine for osteoarthritis (OA).2 We are pleased that the eLetter authors do not put forward any critique of our publication that requires our justification or clarification.
As highlighted by the authors,1 the effectiveness of oral glucosamine products for knee and hip OA symptoms has been questioned. Nevertheless, due to the heterogeneous nature of the disease, whether certain subgroups of patients with OA could benefit from glucosamine has not been excluded. Since available randomised controlled trials are usually not …read more
Citations
More filters
Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank.
Jos Runhaar,Rianne M Rozendaal,M. vanMiddelkoop,J. W. J. Bijlsma,M. Doherty,Krysia Dziedzic,L.S. Lohmander,Timothy E. McAlindon,Weiya Zhang,S.M.A. Bierma-Zeinstra +9 more
TL;DR: There is no goodEvidence to support the use of glucosamine for hip or knee OA and an absence of evidence to support specific consideration of glucOSamine for any clinically relevant OA subgroup according to baseline pain severity, BMI, sex, structural abnormalities or presence of inflammation.
References
More filters
Journal ArticleDOI
Sharing Individual Patient Data from Clinical Trials
TL;DR: An Institute of Medicine committee proposes that clinical trial investigators begin sharing patient-level data more broadly, and honors trial participants' sacrifice by allowing data to be turned into applicable knowledge.
Journal ArticleDOI
Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank.
Jos Runhaar,Rianne M Rozendaal,Marienke van Middelkoop,H. Bijlsma,Michael Doherty,Krysia Dziedzic,L. Stefan Lohmander,Timothy E. McAlindon,Weiya Zhang,Sita Bierma Zeinstra +9 more
TL;DR: In this paper, the authors evaluated the effectiveness of oral glucosamine in subgroups of people with hip or knee osteoarthritis based on baseline pain severity, body mass index (BMI), sex, structural abnormalities and presence of inflammation using individual patient data.
Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank.
Jos Runhaar,Rianne M Rozendaal,M. vanMiddelkoop,J. W. J. Bijlsma,M. Doherty,Krysia Dziedzic,L.S. Lohmander,Timothy E. McAlindon,Weiya Zhang,S.M.A. Bierma-Zeinstra +9 more
TL;DR: There is no goodEvidence to support the use of glucosamine for hip or knee OA and an absence of evidence to support specific consideration of glucOSamine for any clinically relevant OA subgroup according to baseline pain severity, BMI, sex, structural abnormalities or presence of inflammation.
Journal ArticleDOI
Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms.
TL;DR: An elegant meta-analysis of various glucosamine-containing products in knee and hip osteoarthritis (OA), based on individual patient data (IPD), results are in agreement with most glucosamines meta-analyses in OA: glucOSamine products other than prescription crystalline glucosmine sulfate are not effective in hip or knee OA pain and function.
Journal ArticleDOI
Difficulty accessing data from randomised trials of drugs for heart failure: a call for action
Robert Fleetcroft,John Ford,Nicholas D. Gollop,Pieter Mackeith,Kosala Perera,Ashia A Shafi,Jhenaan Sorefan,Caroline Thurlow,Rachel Wakelin,Martin R. Cowie,Nicholas Steel +10 more
TL;DR: When Robert Fleetcroft and colleagues attempted a systematic review of the treatment of heart failure, they were unable to answer their research question because of poor reporting and non-disclosure of data.